Oakland Southfield Physicians

OSP News

Treatment Advances in Type 2 Diabetes

Posted: 05/27/2021

New Glycated Hemoglobin (A1c) Targets

Updated goals from the American Diabetes Association

  • Global: <7%
  • Healthy adults ≥ 55: < 7% - 7.5%
  • Complex patients: < 8%
  • Very complex patients: no target (avoid hypoglycemia and symptomatic hyperglycemia)

Chronic Kidney Disease (CKD)

  • A1c accuracy and precision declines with advanced CKD, in dialysis, or when using erythropoietin-stimulating agents
    • Glucose management derived from Continuous Glucose Monitoring (CGM) may be useful
  • Individualize A1c targets from < 6.5% to < 8.0% based on comorbidities
  • Metformin plus a sodium-glucose cotransporter 2 inhibitor (SGLT2i) can be used as a first-line treatment
  • Avoid SGLT2i treatment if the patient has an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 and stop SGLT2i in dialysis
  • Preferred agents for patients with a low eGFR are a DPP-4 inhibitor, insulin, or a thiazolidinedione
  • Preferred add-on agent for all patients is a long acting GLP-1 receptor agonist

Dyslipidemia

Major risk factors include advancing age, elevated nonhigh-density lipoprotein cholesterol (HDL-C), elevated LDL-C, reduced HDL-C, diabetes, hypertension, CKD, cigarette use, or family history of atherosclerotic cardiovascular disease (ASCVD).

  • High Risk: Diabetes with No Risk Factors
    • LDL-C goal is 100 mg/dL
    • Triglyceride (TG) goal is < 150 mg/dL
    • Recommended treatment is a moderate- to high-intensity statin as needed
  • Very High Risk: Diabetes with 1 or More Risk Factors
    • LDL-C goal is < 70 mg/dL
    • TG goal is < 150 mg/dL
    • Add ezetimibe, a PCKS9 inhibitor, colesevelam, or bempedoic acid, depending on LDL needs
  • Extreme Risk: Diabetes with established clinical ASCVD
    • LDL-C goal is < 55 mg/dL
    • TG goal is < 150 mg/dL
    • Add a PCKS9 inhibitor, ezetimibe, colesevelam, or bempedoic acid, depending on LDL needs
    • For patients with diabetes, 2 or more risk factors and TG 135-499 mg/dL, add icosapent ethyl

Heart Failure

  • For patients with heart failure with reduced ejection fraction (HFrEF), left ventricle ejection fraction less than 45%, the ADA recommends a SGLT2i with proven heart failure benefits
  • Dapagliflozin and Empagliflozin have primary heart failure outcome data
  • Empagliflozin, Canagliflozin, and Dapagliflozin have shown reduction in heart failure and reduction of CKD progression in cardiovascular outcome trials

Overbasalization

  • The 2021 ADA guidelines introduced a new concept: overbasalization, which is characterized as an excessive basal dose of insulin
    • Overbasalization is a potential concern anytime the basal dose exceeds 0.5 units/kg/d
    • Any indication of overbasalization should prompt reevaluation of insulin dosing to reduce glucose variability
  • Too much basal insulin can overcorrect fasting glucose levels, which then rebound to excessive levels. Examples include:
    • Elevated bedtime-morning glucose differential, greater than 50 mg/dL
    • Elevated post-preprandial differential, hypoglycemia, and high glucose variability

New Agents in the Pipeline

  • Tirzepatide - a once-weekly “twincretin” combination of a GLP-1 receptor agonist and a glucose-dependent insulinotropic polypeptide, showed solid phase 3 data in T2D. A cardiovascular outcomes trial is ongoing
  • Insulin icodec - a once-weekly basal insulin, showed efficacy and safety profiles similar to once-daily insulin glargine U100 in T2D

References

  1. https://www.drugtopics.com/view/diabetes-treatment-guidelines-practices-advance-despite-covid-19-focus-in-health-care
  2. Smith JD. New and approved: your annual diabetes update. Presented at: American Pharmacists Association 2021 Annual Meeting and Exposition; March 12-15, 2021; virtual. Accessed March 12, 2021. https://apha2021.pharmacist.com/ 

 

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.

x

OSP Technical Support